Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion.

Tang J, Pulliam N, Özeş A, Buechlein A, Ding N, Keer H, Rusch D, O'Hagan H, Stack MS, Nephew KP.

Mol Cancer Res. 2018 Aug;16(8):1226-1240. doi: 10.1158/1541-7786.MCR-17-0406. Epub 2018 May 14.

PMID:
29759990
2.

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.

Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, Lyons J, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP.

Clin Cancer Res. 2018 Jul 1;24(13):3163-3175. doi: 10.1158/1078-0432.CCR-18-0204. Epub 2018 Apr 3.

PMID:
29615458
3.

Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.

Özeş AR, Pulliam N, Ertosun MG, Yılmaz Ö, Tang J, Çopuroğlu E, Matei D, Özeş ON, Nephew KP.

Oncogene. 2018 Jun;37(26):3589-3600. doi: 10.1038/s41388-018-0218-z. Epub 2018 Mar 26.

4.

Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.

Haley J, Tomar S, Pulliam N, Xiong S, Perkins SM, Karpf AR, Mitra S, Nephew KP, Mitra AK.

Oncotarget. 2016 May 31;7(22):32810-20. doi: 10.18632/oncotarget.9053.

5.

Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.

Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharyya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A, Singhal SB.

J Immunol. 2013 Mar 15;190(6):2966-75. doi: 10.4049/jimmunol.1202493. Epub 2013 Feb 13.

Supplemental Content

Loading ...
Support Center